Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25

AUSTIN, Texas, March 5, 2015 /PRNewswire/ -- Vermillion, Inc. VRML, a bio-analytical solutions company focused on gynecologic disease, announced today it will report fourth quarter and 2014 financial results before the market open on Wednesday, March 25, 2015, followed by an investor conference call and webcast at 8:30am Eastern.

About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic disease. The company's lead diagnostic, OVA1^®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vermillion-to-report-fourth-quarter-and-year-end-2014-financial-results-and-host-an-investor-conference-call-on-march-25-300045602.html

SOURCE Vermillion, Inc.